Ergomed plc
Ergomed plc Fundamental Analysis
Ergomed plc (2EM.DE) shows weak financial fundamentals with a PE ratio of 32.74, profit margin of 10.31%, and ROE of 19.71%. The company generates $0.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 68.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 2EM.DE's fundamental strength across five key dimensions:
Efficiency Score
Excellent2EM.DE demonstrates superior asset utilization.
Valuation Score
Moderate2EM.DE shows balanced valuation metrics.
Growth Score
Moderate2EM.DE shows steady but slowing expansion.
Financial Health Score
Excellent2EM.DE maintains a strong and stable balance sheet.
Profitability Score
Moderate2EM.DE maintains healthy but balanced margins.
Key Financial Metrics
Is 2EM.DE Expensive or Cheap?
P/E Ratio
2EM.DE trades at 32.74 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 2EM.DE's PEG of 0.38 indicates potential undervaluation.
Price to Book
The market values Ergomed plc at 5.79 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 21.88 times EBITDA. This signals the market has high growth expectations.
How Well Does 2EM.DE Make Money?
Net Profit Margin
For every $100 in sales, Ergomed plc keeps $10.31 as profit after all expenses.
Operating Margin
Core operations generate 14.14 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $19.71 in profit for every $100 of shareholder equity.
ROA
Ergomed plc generates $11.58 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Ergomed plc produces operating cash flow of $15.47M, showing steady but balanced cash generation.
Free Cash Flow
Ergomed plc produces free cash flow of $13.48M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.25 in free cash annually.
FCF Yield
2EM.DE converts 2.53% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
32.74
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.38
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.79
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.52
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.50
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.12
vs 25 benchmark
ROCE
Return on capital employed
0.23
vs 25 benchmark
How 2EM.DE Stacks Against Its Sector Peers
| Metric | 2EM.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 32.74 | 28.54 | Worse (Expensive) |
| ROE | 19.71% | 738.00% | Weak |
| Net Margin | 10.31% | -43982.00% (disorted) | Strong |
| Debt/Equity | 0.03 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.50 | 2806.01 | Neutral |
| ROA | 11.58% | -14624.00% (disorted) | Strong |
2EM.DE outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Ergomed plc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation